EKF Diagnostics Holdings plc (LSE:EKF) has told shareholders that much of its growth this year is expected to arrive in the second half. Its interim report described a flat first half in point-of-care testing, attributed largely to timing, alongside expectations of higher orders later in 2026. The question is why the company is leaning on the second half and what supports that view.
Diagnostics devices and life sciences
EKF Diagnostics is quoted on AIM under the code EKF. It operates two divisions. Point-of-Care sells diagnostic analysers and consumables, including haematology products such as HemataSTAT and Hemo Control. Life Sciences supplies reagents, notably its beta-hydroxybutyrate (β-HB) LiquiColor test, and provides fermentation and contract Manufacturing services, which now operate under the Nexus Bioworks brand. The company is led by chief executive Gavin Jones, with Helen Jones appointed chief financial officer in April 2026.
The 15 September interim results
On 15 September 2026, EKF reported Revenue of £25.0 million for the six months to 30 June 2026, broadly flat on £25.2 million. Point-of-Care revenue fell 3% to £15.0 million, while Life Sciences grew 8% to £10.0 million. The chief executive said: "Point-of-Care has been broadly flat in the first half; however, this is largely due to the timing of key initiatives."
Specific examples were given. Haematology revenue was stable at £7.8 million, with Egyptian Business shifting into the second half, while HemataSTAT revenue grew 9% year on year. β-HB reagent sales grew 4% to £7.4 million, and management said it expects a "significant β-HB pick-up in the second half of 2026" after customer inventory levels normalised. Within Life Sciences, fermentation revenue rose 14% to £1.6 million and contract manufacturing grew 25% to £1.0 million, which suggests the services side is contributing to divisional growth. The company also said it had "clear visibility on continued, significant Supply to our key partners".
Margins, cash and buybacks
Gross Margin improved to 53.0% from 50.2%, and adjusted EBITDA rose to £5.9 million from £5.8 million. Operating profit eased to £3.3 million and profit before tax to £3.4 million. Basic Earnings Per Share rose to 0.54p from 0.43p; the smaller share count may have contributed somewhat. Cash stood at £16.0 million, although £2.4 million is restricted in Russia because of sanctions, and cash generated from operations fell to £3.3 million from £4.9 million.
The company has continued buying back shares for cancellation. A notice published on 29 September 2026 said cumulative purchases under the programme, first announced in May 2025 and extended in February 2026, totalled 21,125,398 shares, leaving 427,968,392 shares in issue. In the first half, it bought and cancelled 3.554 million shares at a cost of £0.9 million.
Other developments included completing the Beep Insights acquisition, a lactate tracking technology, and fully exiting its former Elkhart, Indiana site a year earlier than planned. Expansion of Hemo Control consumables capacity by a further 30% remains on track for 2027.
Risks to watch
Guidance for revenue and adjusted EBITDA growth "in line with market expectations" depends on second-half deliveries, including the deferred Egyptian haematology business and the β-HB recovery. If orders slip, full-year results could fall short of consensus forecasts cited by the company of £54.6 million revenue and £13.6 million adjusted EBITDA. Restricted Russian cash, where future Dividend receipts are uncertain, lower Operating Cash Flow and an expired £3 million Facility are further considerations, although directors affirmed Going Concern under worst-case scenarios.
Conclusion
EKF is relying on its second half because, according to the company, flat first-half Point-of-Care sales reflected timing, with Egyptian haematology orders and β-HB Demand expected later in the year. Improved margins and continued Buybacks provide some support, but the reported first-half numbers mean full-year delivery depends on those orders arriving as planned.






Please wait processing your request...